热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易

客户端

　　晶泰控股-P（02228）发布公告，集团预期截至2024年12月31日止年度透过提供药物发现解决方案及智能自动化解决方案所产生的收入将达到已商业化公司（定义见上市规则第18C章）的收入门槛，即2.5亿港元。该等收入乃由于本集团于截至2024年12月31日止年度的业务发展及市场机遇所致。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：卢昱君

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.